Skip to content

Developing More Clinically Safe & Efficacious Therapeutics for GI Inflammatory Diseases

The GI Inflammatory Diseases Summit (GIIDS) focuses exclusively on overcoming translational drug development challenges to achieve more clinically safe and efficacious therapeutics for Inflammatory Bowel Disease.

Incorporating insights from leading pharma and pioneering biotech, this discussion and networking forum will curate the cutting edge insights on:

  • Improving drug safety profiles of more gut-selective compounds
  • Optimizing trial design in a hypercompetitive market
  • The promise of microbiome based biotherapeutics

Join gastroenterology, immunology and anti-inflammatory drug developers at this unique conference and push the clinical frontier nearer to achieving significant clinical remission in larger groups of patients.

Thought this disease specific conference was informative, by planning a concentrated topic it gave an opportunity to look through a tighter lens.
Genentech

The conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!
AstraZeneca

This is my 3rd Hanson Wade conference and I have left each time very satisfied having considerably improved my knowledge base and meeting some serious experts in the field.
Daichii Sankyo

*Quotes taken from previous Hanson Wade events*